Yonsei, REPUBLIC OF KOREA - 30 Aug `18Investigation on the Expression of HMGB1

Official Title: The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity

In Brief: Vitiligo is an acquired depigmented disorder that causes white spots on the skin due to the loss of melanocytes. It is a common disease which accounts for 0.5-1% of the whole population. It is a refractory skin disease with 25-50 thousand patients in Korea. And it is often caused in the exposed areas of the patient, causing a great deal of mental and social dysfunction in the patient's life, and may lead to suicide attempts.

Ages Eligible: 19 Years and older

Start Date: August 30, 2018

Completion Date (estimated): August 29, 2020

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03741738

Location: Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, 03722

Contact: To learn more about this study, you or your doctor may contact Sang Ho Oh, MD, PhD by phone +82 2 2228 2080 or email oddung93@yuhs.ac. Please refer to this study by its NCT number.

FAQOther Questions

  • How long does it take to treat vitiligo?

    Treatment results will vary by person and type of vitiligo. The rule of thumb is that you will need to allow at least 3 to 6 months before you begin to see results from any trea...

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba seems to be a simple, safe, inexpensive and fairly effective therapy for vitiligo. It is mostly effective in halting the progression of the disease. It can also sp...

  • Are there any famous people with vitiligo?

    Many celebrities have dealt with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career. Here are a few courageous famous peo...